Circulating microRNAs: Possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma

Clinical Lung Cancer

Volumn 12, Issue 1, 2011, Pages 14-17

  Gao, Wen ^a   Liu, Lingxiang ^a   Lu, Xiao ^a   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

4 MicroRNA signature; qRT PCR; Solexa

Indexed keywords

BIOLOGICAL MARKER; GEMCITABINE; MICRORNA; MICRORNA 1; MICRORNA 106A; MICRORNA 146; MICRORNA 15; MICRORNA 155; MICRORNA 16; MICRORNA 173P; MICRORNA 191; MICRORNA 192; MICRORNA 200; MICRORNA 203; MICRORNA 205; MICRORNA 21; MICRORNA 210; MICRORNA 211; MICRORNA 212; MICRORNA 214; MICRORNA 222; MICRORNA 223; MICRORNA 25; MICRORNA 30D; MICRORNA 486; MICRORNA 499; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; GENE EXPRESSION; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PLASMA; REAL TIME POLYMERASE CHAIN REACTION; SERUM;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551542904     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.3816/CLC.2011.n.001     Document Type: Article

References (35)

1. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non small cell lung cancer. Aphase III randomized study of the London Cancer Group. J Clin Oncol 2005;23:142-53.
2. Martoni A, Marino A, Sperandi F, et al. Multicentre randomized phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005;41:81-92.
3. Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006;16:4-9
4. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
6. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 miRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6.
7. Yanaihara N, Caplen N, Bowman E, et al. Unique miRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
8. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 miRNA family. Cell 2005;120:635-47.
9. Yu SL, Chen HY, Chang GC, et al. MiRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2007;13:48-57.
10. Gao W, Yu Y, Cao HL, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomedicine & Pharmacotherapy 2010;64:399-408.
11. Yan LX, Huang XF, Shao Q, et al. MiRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348-60.
12. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8.
13. Chen X, Ba Y, Ma L, et al. Characterization of miRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
14. Hu ZB, Chen X, Zhao Y, et al. Serum microRNA Signatures Identified in a Genome-Wide Serum MicroRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010;28:1721-6.
15. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
16. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008;27:3845-55.
17. Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensi-tivity of tumor cells. Mol Cancer Ther 2008;7:1-9.
18. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroen-terology 2006;130:2113-29.
19. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007;26:2799-803.
20. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-33.
21. Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008;123:372-9.
22. Yang N, Kaur S, Volinia S, et al. MicroRNA microarray identifies let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008;68:10307-14.
23. Li Y, Van den Boom TG, 2nd, Kong D. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009;69:6704-12.
24. Rabinowits G, Gerçel-Taylor C, Day JM, et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009;10:42-6.
25. Resnick KE, Alder H, Hagan J P. The detection of differentially expressed mi-croRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009;112:55-9.
26. Zhu W, Qin WY, Atasoy U, et al. Circulating microRNAs in breast cancer and healthy subjects. BMC Research Notes 2009;2:89.
27. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.
28. Wang J, Chen J, Chang P. MicroRNAs in plasma of pancreatic ductal adenocarci-noma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila Pa) 2009;2:807-13.
29. Slaby O, Svoboda M, Michalek J, et al. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009;8:102.
30. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomark-ers for early detection of colorectal cancer. Int J Cancer 2010;127:118-26.
31. Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with serum microR-NAs on an oligonucleotide microarray. PLoS ONE 2009;4: e6229.
32. Shlomit G, Eti M, Yariv Y, et al. Serum microRNAs are promising novel biomark-ers. PLoS ONE 2009;3: e3148.
33. Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010;391:73-7.
34. Ji X, Takahashi R, Hiura Y, et al. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009;55:1944-9.
35. Vasilescu C, Rossi S, Shimizu M, et al. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS ONE 2009;4: e7405.